New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 14, 2019 - Merz Pharmaceuticals announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment of blepharospasm in adult patients.
Download PDF
Return to publications
